Microcirculatory adaptations in sickle cell anemia: reactive hyperemia response

1990 ◽  
Vol 258 (1) ◽  
pp. H113-H120 ◽  
Author(s):  
G. P. Rodgers ◽  
A. N. Schechter ◽  
C. T. Noguchi ◽  
H. G. Klein ◽  
A. W. Nienhuis ◽  
...  

With the technique of laser-Doppler velocimetry, cutaneous blood flows in the forearm of patients with stable sickle cell disease after graded periods of proximal ischemia were compared with normal subjects matched for age, race, and sex, and with patients with anemia caused by beta(+)-thalassemia. In the sickle cell patients the reactive hyperemia was characterized by an increased time interval between the release of the occlusion and the peak amplitude response (time-to-peak) and by a greater period of blood flow above the base-line value (payback ratio) compared with controls. In addition, prolongation of the occlusion period led to an augmentation in the magnitude of the characteristic basal flow oscillations or an induction of this phenomenon at sites not exhibiting it before ischemia. Base-line or ischemia-provoked flow oscillations of either this magnitude or frequency were only observed in normal or thalassemic controls during brief intervals in the rapidly decaying portion of the hyperemic response and in one subject with homozygous hemoglobin C disease. These results would support a model of a local integrative control of microcirculatory blood flow, which appears to become augmented, synchronized, and sustained in sickle cell subjects.

1961 ◽  
Vol 16 (5) ◽  
pp. 851-857 ◽  
Author(s):  
David I. Abramson ◽  
Samuel Tuck ◽  
Yvonne Bell ◽  
Roscoe E. Mitchell ◽  
Agenor M. Zayas

In 17 experiments, performed on the forearm of normal subjects, the effect of 2½, 5, and 10 min of arterial occlusion was studied. Blood flow was obtained with the venous occlusion plethysmograph, and oxygen uptake was calculated using the Fick principle. Arterial occlusion resulted in the production of an oxygen debt which was subsequently repaid. With progressively longer periods of anoxia there was a proportionate increase in the magnitude of the debt. Similar conclusions could not be drawn from blood flow studies alone, since the vascular change represented only one means of repayment of the oxygen debt during reactive hyperemia, the other being a greater extraction of oxygen from each unit of blood early in the postocclusion period. The constant overswing on either side of the control base line, observed in the records of oxygen uptake, suggested the absence of delicately balanced and efficient checks on the mechanisms responsible for repayment of the oxygen debt incurred in the period of tissue anoxia. Submitted on March 27, 1961


Metabolism ◽  
2001 ◽  
Vol 50 (4) ◽  
pp. 387-392 ◽  
Author(s):  
Jan C. ter Maaten ◽  
Erik H. Serné ◽  
Stephan J.L. Bakker ◽  
Wim Statius van Eps ◽  
Ab J.M. Donker ◽  
...  

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 1059-1059
Author(s):  
Janice Earl ◽  
Peter Sun ◽  
Kenneth Martin ◽  
Keith C. Quirolo ◽  
Elliott Vichinsky ◽  
...  

Abstract Abstract 1059 Background: Moyamoya disease is a progressive cerebrovascular complication of sickle cell anemia characterized by collateral arterial formation in response to progressive stenosis of the large intracranial arteries. Despite chronic transfusions, moyamoya is associated with a high risk of stroke recurrence. Encephaloduroarteriosynangiosis (EDAS) is a surgical technique used to reestablish or augment cerebral perfusion in patients with moyamoya disease. However, evidence for its efficacy in SCA patients is limited. We initiated a prospective study to determine whether EDAS is safe and increases blood flow to ischemic areas of brain in SCA patients with moyamoya. Methods/Results: SCA patients who had complete or partial obstruction of the dICA with progression to moyamoya disease were eligible for EDAS. Progressive cognitive decline, dystonia and persistent seizures were also factors influencing eligibility. Seven SCA patients (age: median 16yrs, range 4–23yrs; sex: 5F/2M ) with moyamoya disease underwent encephaloduroarteriosynangiosis (EDAS) procedures between 3/2007 and 9/2010. All 7 patients were regularly transfused for a history of stroke or MRA-documented ICA stenosis. Complete or partial obstruction of the dICA with moyamoya changes was detected on MRA scans and confirmed by cerebral angiography. Bilateral (n = 2) or unilateral (n = 5) encephaloduroarteriosynangiosis procedures in which the superficial temporal artery is transplanted through a small craniotomy with dural and arachnoid opening and sutured to the pia were performed. Perfusion MR-weighted imaging was performed pre- and post-operatively to evaluate changes in relative cerebral blood volume and time to peak enhancement. Results: All patients have remained free of neurovascular complications and have had no new ischemic changes on MRI with an average follow-up of 26 months. All patients subjectively reported improvement in overall well-being. A decrease in the frequency of headaches (n=1), resolution of seizures (n=2) and improved gait (n=1) were also observed. Collateral anastomoses between external and internal carotid arteries were established by MRA in all patients. All 4 patients who had pre and post-procedure MRA perfusion imaging showed a reduction in the delay of time to peak enhancement in the affected territory after EDAS. Conclusion: Our results indicate that EDAS is a safe and effective surgical procedure to re-establish blood flow to ischemic brain tissue in patients with SCA who develop moyamoya disease. MRA perfusion imaging may be a useful tool to evaluate improved perfusion status after EDAS. Further examination of neuropsychologic correlates, such as executive function, with EDAS procedures in these patients is presently underway. Disclosures: Vichinsky: Novartis: Research Funding; Apotex: Research Funding.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 3670-3670
Author(s):  
Ofelia A. Alvarez ◽  
Tally Hustace ◽  
Mimose Voltaire ◽  
Rodrigueson Rizil ◽  
Ulrick Liberus ◽  
...  

Abstract Introduction: Until 2017, hemoglobinopathy newborn screening (NBS) was not offered in Haiti, a country with about 243,000 births per year. Sickle SCAN is a rapid point-of-care (POC) with lateral flow immunoassay technology, but its role in NBS is unknown. Recently, over 100 dried blood samples from newborns were tested [Nguyen-Khoa T, Ann Biol Clin (Paris), 2018] in France with accurate results. Objective: This work had the objective to be proof-of-concept that a hospital-based NBS program is feasible in Haiti and to examine the role of Sickle SCAN in NBS in a larger sample size. Methods: The Ethics Committee at the Universitaire Justinien Hospital (HUJ) and the Institutional Review Board at the University of Miami approved this study. We formed a Haitian team composed of a pediatrician on staff (RSF), two dedicated NBS nurses, a program coordinator (MV), two community health workers, a laboratory technician (RR), and a data manager (UL). We acquired isoelectric focusing equipment (IEF) and performed NBS from dried blood samples only for the first three months while the technician gained proficiency. Thereafter, we have performed dual screening method with the POC device Sickle SCAN and IEF. Confirmatory testing was obtained with both methods. Data were entered into RED Cap. Results: Beginning in August 2017 until present (June 2018), we have screened 1,800 newborns, of which 10.5% have sickle cell trait, 3.3% have hemoglobin C trait, 0.78% have hemoglobin SS, 0.27% have hemoglobin SC and one child has been confirmed to have sickle beta thalassemia plus. Currently, there are 15 children followed at HUJ, for a SCD incidence of 0.83% (8 SS, 6 SC and 1 S-beta thalassemia+). Before the POC screening was implemented two infants have already died when the mothers were contacted (one who screened positive for FS and another for FC). The POC allows for immediate referral and penicillin prophylaxis for at-risk children until the cases are confirmed. Systemic barriers encountered are the electrical outages and intense heat which impacted IEF performance, material procurement (laboratory materials, NBS materials, oral penicillin) which are dependent of shipments from outside of Haiti. Conclusions: A hospital-based NBS Program is feasible. SCD is highly prevalent with an incidence of 0.83% among newborns in the population studied. Based on this incidence, we estimate that every year around 2,000 children will be born with sickle cell disease in Haiti. The point-of-care device enhanced the screening program by obtaining immediate screening results and maximizing family notification for confirmatory testing. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4824-4824
Author(s):  
Alice J. Cohen ◽  
Chaim Tuckman-Vernon

Abstract Pulmonary hypertension (PH) is a common complication of sickle cell disease (SD) and a significant cause of morbidity and mortality. PH, measured by Doppler echocardiography and defined as a tricuspid regurgitant jet velocity (TRV) > 2.5 m per second (m/s), is hypothesized to be related to the chronic hemolytic anemia of SD, but causality is unproven. If so, the presence of hemoglobin C, which reduces hemolysis, would be expected to have a reduced likelihood of PH. This study reviewed the prevalence of PH in 3 categories of patients with SD: homozygous S (SS), sickle-beta thalassemia (SB), and SC. Methods: Sickle cell disease patients registered at a state funded community comprehensive care adult sickle cell center were routinely screened for PH by Doppler echocardiography. The presence of PH, the incidence of a related complication, acute chest syndrome (ACS), and baseline hemoglobin (hgb) were reviewed. Results: 16 patients with SC type, 30 with SS and 39 with SB disease underwent screening. The prevalence of PH, ACS and hgb are listed in the table below. Conclusion: SC patients have PH and ACS similar to patients with SS and SB patients. These patients have higher baseline hemoglobin and may have hyperviscosity as a cause of PH and ACS as opposed to hemolytic anemia. Further study of PH and ACS in SC patients is warranted. SC SS SB p value PH 6/16 (38%) 12/40 (40%) 11/39 (28%) p= NS ACS 7/16 (44%) 10/30 (33%) 19/39 (49%) p=NS PH + ACS 4/16 (25%) 5/30 (17%) 4/39 (10%) p=NS ACS in PH patients 4/6 (67%) 5/12 (42%) 4/11 (36%) p-=NS Hgb 10.8 7.89 8.57 p=0.000


2019 ◽  
Author(s):  
CC Martino ◽  
CS Alencar ◽  
P Loureiro ◽  
AB Carneiro-Proietti ◽  
CA Máximo ◽  
...  

ABSTRACTBackgroundThe diagnosis of sickle cell disease (SCD) is made by hemoglobin assays such as high-performance liquid chromatography (HPLC), isoelectric focusing and cellulose acetate or citrate agar electrophoresis. These assays are easy to perform and used in large-scale newborn screening in many countries. These tests however may not easily differentiate Sβ0 thalassemia from SS or identify other hemoglobin variants, and in this case, hemoglobin (HBB) gene sequencing may be necessary.ObjectivesTo develop a high throughput DNA based confirmatory assay for SCD and to detect mutations in the HBB gene.MethodsWe developed an automated pyrosequencing technique (PyS) based on QIAGEN technology (Hilden, Germany) to detect homozygous or heterozygous hemoglobin S mutations as well as hemoglobin C mutations. The technique was tested on 2,748 samples from patients enrolled in a multi-center SCD cohort in Brazil. Patients were previously tested using HPLC to diagnose SCD as part of routine clinical care. Any subjects with discrepant results between HPLC and PyS or with heterozygous hemoglobin S detected had Sanger sequencing of the HBB gene.ResultsWe identified 168 samples with discrepant results between HPLC and PyS and 100 with concordant HPLC and PyS= heterozygous S, which would suggest Sβ-thalassemia or other hemoglobin S variants. The PyS assay correctly identified 1906 (98.7%) of the 1930 HbSS and 628 (98.7%) of the 636 HbSC samples. Of the 179 remaining samples, PyS correctly indicated S heterozygosis in 165 (92.2%). Of the 165 heterozygous S samples confirmed by Sanger as consistent with Sβ thalassemia genotype, 84 samples were classified as Sβ0 thalassemia and 81 as Sβ+ thalassemia. The most frequent beta thalassemia mutations of Sβ0 and Sβ+ were HBB: c.118C>T (Gln40Stop) and HBB c.92 + 6T> C, respectively.DiscussionThe PyS proved to be satisfactory for large-scale confirmatory testing of hemoglobin mutation. Moreover, with this study we were able to describe the most common β+ and β0 mutations in SCD patients with Sβ-thalassemia in a large multi-institutional SCD cohort in Brazil.


1991 ◽  
Vol 81 (2) ◽  
pp. 57-61 ◽  
Author(s):  
AF Hoffman ◽  
BA Schmugler ◽  
MJ Matthews

The authors report digital pressure changes in normal subjects following the 5-min postocclusive reactive hyperemia test. This test increases the sensitivity of using toe pressures to assess the adequacy of blood flow.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2486-2486
Author(s):  
Megan L. Krajewski ◽  
James A. Kim ◽  
Laurel G. Mendelsohn ◽  
Candice B. Williams ◽  
Mark T. Gladwin ◽  
...  

Abstract Background: Decreased nitric oxide (NO) bioavailability is increasingly recognized as an important contributor to endothelial dysfunction and vascular complications of sickle cell disease. Unlike in other states of endothelial dysfunction, where NO production is impaired but response to exogenous NO donors is preserved, the vascular dysfunction observed in sickle cell disease is characterized by a diminished response to NO donors. Our group has previously demonstrated this NO resistance state through invasive strain-gauge venous occlusion plethysmography, the gold standard for evaluating peripheral endothelial function. Reactive hyperemia-peripheral arterial tonometry (RH-PAT) (ENDO-PAT 2000, Itamar Medical) is a relatively new, non-invasive technique for assessing endothelial function that records the reactive hyperemia response by measuring finger pulse wave amplitude after occlusion of the arm. We sought to compare these two techniques and validate peripheral arterial tonometry (PAT) as a tool for assessing vascular function in the sickle cell population. Methods: Thirteen patients with HbSS sickle cell disease have participated in this ongoing study. Subjects were recruited while in steady state and were not receiving chronic transfusions. Following an overnight fast, subjects underwent PAT. According to manufacturer specifications, RH-PAT indices ≤ 1.67 are indicative of endothelial dysfunction and those > 1.67 represent normal endothelial function. The subjects subsequently underwent venous occlusion plethysmography (AI6, D.E. Hokanson, Inc). Infusions of acetylcholine (ACh) and sodium nitroprusside (SNP) were administered to measure endothelium-dependent and endothelium-independent blood flow, respectively. To further characterize the nitric oxide resistance state, plasma samples from the first eight patients were assayed for NO consumption, and nitrite, a NO metabolite. Results: Following intra-arterial infusion of 7.5, 15, and 30 μg/min of ACh, patients with an RH-PAT index ≤ 1.67 had an increase in blood flow over baseline of 196 ± 30%, 287 ± 43%, and 338 ± 53%, respectively. This was not significantly different from the percentage change in blood flow response in patients with RH-PAT index > 1.67 (281 ± 68%, 277 ± 48%, 407 ± 53%, respectively, p = 0.60). In contrast, patients with an RHPAT index ≤ 1.67 demonstrated a significantly blunted response to 0.8, 1.6, and 3.2 μg/min infusions of SNP (28 ± 7%, 45 ± 11%, and 76 ± 17% vs. 85 ± 18%, 142 ± 36%, and 240 ± 48%, respectively, p < 0.001). This blunted response was also observed when comparing absolute forearm flow values (p < 0.01). Lactate dehydrogenase, an established biomarker of the NO resistance state and associated endothelial dysfunction in sickle cell disease, was found to be inversely correlated with plasma nitrite levels (Spearman r = −0.95, p = 0.001). Plasma nitrite levels were also inversely correlated with NO consumption (Pearson r = −0.80, 95% CI = −0.96 to −0.23, p = 0.016). Patients with an RH-PAT ≤ 1.67 demonstrated greater NO consumption than patients with an RH-PAT > 1.67 (3.32 μM ± 0.49, n = 4 vs. 2.06 μM ± 0.18, n = 4, (mean ± SEM), p= 0.029), consistent with a state of decreased NO bioavailability. Plasma nitrite reserve in patients with sickle cell disease has not been clearly established, but these data suggest a potential relationship between decreased nitrite and NO resistance. Interestingly, decreased plasma nitrite levels have been shown to correlate with endothelial dysfunction in other patient populations. Conclusions: In this cohort of sickle cell patients, RH-PAT was closely associated with the NO-mediated component of endothelial function. Lower RH-PAT is associated with blunted response to SNP and increased NO consumption, suggesting that RH-PAT provides a non-invasive method for assessing NO resistance in sickle cell disease. In addition, our results present preliminary support that plasma hemoglobin redirects NO metabolism away from nitrite production.


Sign in / Sign up

Export Citation Format

Share Document